Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Chuikyo to Discuss 2023 Off-Year Re-Pricing with Its Implementation as Premise: MHLW
October 27, 2022
- LDP to Launch Lawmakers’ League on Medical Adhesive Patches
October 27, 2022
- Bill to Amend Infectious Disease Act and Other Laws Enter Diet Deliberations
October 26, 2022
- Pfizer Assesses Cancer Risk from Amoxan as “Acceptable” at “1 in 200,000 People”
October 26, 2022
- New Economic Package to Drive Antibiotic API Production, Vaccine Trials in Japan
October 25, 2022
- Commodity Prices Are Rising, That’s Why Full Drug Re-Pricing Needed in 2023: MOF Official
October 25, 2022
- Moderna’s BA.4/5 COVID Jab Up for PAFSC Review on Oct. 31
October 25, 2022
- Early Approval, Reimbursement of SaMD Put on Priority Agenda: Deregulation Panel
October 25, 2022
- Japan Might Change Timing of Drug Price Revisions from April amid Medical DX Push
October 24, 2022
- Nearly 700 Key Drugs Found to Be Unprofitable Due to Inflation, FX: Survey
October 24, 2022
- Is New Expert Panel All about Drug Pricing System? Asks Chair
October 24, 2022
- Experts Call for Debate on Scope of Health Coverage, “Exit Rule” for Unnecessary Meds
October 24, 2022
- PMDA Reviewing New Safety Risks for Evrenzo and More Drugs
October 24, 2022
- With Shortened Interval, Omicron Booster Likely to Cover 18 Million More People by Month-End
October 21, 2022
- LDP Project Team to Present Proposal for FY2023 Drug Price Revision and Budget Planning
October 21, 2022
- COVID Booster Interval to Be Shortened to “At Least 3 Months”
October 20, 2022
- Silgard 9’s Label Updated to Add Long-Term Follow-Up Study Data
October 19, 2022
- Avigan Secured for COVID-19 to Be Stockpiled for Pandemic Flu: Health Minister
October 19, 2022
- Label Expansions for TS-1, Enhertu on PAFSC Agenda on Oct. 31
October 18, 2022
- Japan Panel Recognizes One More Death Possibly Linked to COVID Jab
October 18, 2022
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…